Read More

Celyad Oncology Reports Q3 Financial Review As Of September 30, The Company Had Cash And Cash Equivalents Of $13.1M; Clinical Updates Expected By End Of Year For The Phase 1 Dose-escalation IMMUNICY-1 Trial For Lead ShRNA-based Allogeneic Car T Candida…

Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discovery Clinical updates expected by end of year for the Phase 1 dose-escalation

CYAD